Effects of Sulphasalazine and Glucocorticoid on the Regulation of CCL20 Gene Expression in the Peripheral Blood Cells of Korean Patients with Ulcerative Colitis.
- Author:
Suck Chei CHOI
1
;
Yong Ho NAH
;
Yeun Tai CHUNG
;
Won Cheol HAN
;
Myeung Su LEE
;
Chang Duk JUN
Author Information
1. Department of Gastroenterology, Wonkwang University, School of Medicine, Korea.
- Publication Type:Original Article
- Keywords:
Inflammatory bowel disease;
Ulcerative colitis;
Crohn's disease;
CCL20;
Anti-inflammatory agent
- MeSH:
Adaptive Immunity;
Blood Cells*;
Colitis, Ulcerative*;
Crohn Disease;
Dexamethasone;
Epithelial Cells;
Epithelium;
Follow-Up Studies;
Gene Expression*;
HT29 Cells;
Humans;
Inflammatory Bowel Diseases;
Intestinal Mucosa;
Korea;
RNA, Messenger;
Salicylic Acid;
Sulfasalazine*;
Ulcer*
- From:Korean Journal of Anatomy
2004;37(6):549-555
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Discovery of Nod2 has brought to light the significance of mononuclear cells as well as epithelial cells in inflammatory bowel disease (IBD) pathogenesis. Similarly, CCL20 is expressed in both mononuclear cells and epithelial cells and is likely to link innate and acquired immunity. We therefore asked whether CCL20 expression is altered in the peripheral blood mononuclear cells (PBMCs) from patients with ulcerative colitis (UC), a major type of IBD in Korea, and is correlated with the disease activity. The expression levels of CCL20 mRNA were significantly high in the PBMCs from the patients with UC. CCL20 protein expression was also up-regulated in the mucosal epithelium in UC but not in normal controls. Interestingly, however, disease activity index (DAI) revealed that untreated UC groups express higher expression levels of CCL20 mRNA than treated UC groups, implying that CCL20 may be a potential target for the anti-inflammatory treatments. In an agreement with this, three months follow up study revealed that the UC patients who were treated with 5-amino salicylic acid (5-ASA) and glucocorticoid showed dramatic decrease in their CCL20 mRNA levels as compared to untreated ones. Moreover, TNF-alpha-or IL-1beta-induced CCL20 secretion in human epithelial HT-29 cells was significantly diminished by the treatment with 5-ASA and/or dexamethasone, suggesting that CCL20 may be one of the central targets of the anti-inflammatory drugs. Collectively, these results suggest that CCL20 expression in UC may be associated with altered immune and inflammatory responses in the blood as well as the intestinal mucosa and further implied a potential for CCL20 as an important diagnostic marker for UC.
